Allos' pralatrexate shows activity in several cancer cell lines

US drug developer Allos Therapeutics reported new data at the annual meeting of the American Association for Cancer Research in Denver,  Colorado, demonstrating the anticancer activity of its investigational  drug, pralatrexate, in colon, ovarian, lung, prostate and head and neck  cancer cell lines.

The preclinical research further showed that the antiproliferative  effects against these cancer lines were achieved at drug concentrations  that are attainable in humans, the firm noted.

The company's lead product candidate, pralatrexate, is a novel-targeted  antifolate designed to accumulate preferentially in cancer cells. Allos  submitted a New Drug Application to the US Food and Drug Administration  for the agent the treatment of relapsed or refractory peripheral T-cell  lymphoma in March.